Nikolaos A Chatzizacharias1, Susan Tsai1, Michael Griffin2, Parag Tolat2, Paul Ritch3, Ben George3, Chad Barnes1, Mohammed Aldakkak1, Abdul H Khan4, William Hall5, Beth Erickson5, Douglas B Evans1, Kathleen K Christians6. 1. Department of Surgery, Division of Surgical Oncology, Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA. 2. Department of Radiology, Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA. 3. Department of Medicine, Divisions of Medical Oncology, Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA. 4. Department of Gastroenterology, Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA. 5. Department of Radiation Oncology, Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA. 6. Department of Surgery, Division of Surgical Oncology, Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address: kchristi@mcw.edu.
Abstract
BACKGROUND: Patients with locally advanced pancreatic cancer have historically been considered inoperable. The purpose of this report was to determine resectability rates for patients with locally advanced pancreatic cancer based on our recently described definitions of type A and type B locally advanced pancreatic cancer. METHODS: An institutional prospective pancreas cancer database was queried for consecutive patients with locally advanced pancreatic cancer treated between January 2009 and June 2017. All pretreatment imaging was re-reviewed and patients were categorized as locally advanced pancreatic cancer type A or type B. Demographics, induction therapy, resection type, and outcomes were reviewed. RESULTS: We identified 108 consecutive patients; 12 were excluded from analysis due to the absence of available pretreatment imaging or they had not yet completed all intended neoadjuvant therapy. Of the remaining 96 patients (45 type A, 51 type B), disease progression occurred in 19 (20%) during induction therapy and 30 (31%) were deemed inoperable at final preoperative restaging. Therefore, 47 (49%) of 96 patients were taken to surgery and 40 (42%) underwent successful resection (28 [62%] of 45 type A and 12 [24%] of 51 type B); an RO resection was achieved in 32 (80%). Metastatic disease was found intraoperatively (6 at laparoscopy, 1 at laparotomy) in 7 (15%) of 47 patients. There were no mortalities; 6 (15%) patients experienced major postoperative complications. Resected patients had a median overall survival of 38.9 months. CONCLUSION: Locally advanced pancreatic cancer can be dichotomized into type A and B with distinctly different probabilities of completing all therapy to include surgery; thereby allowing goals of therapy to be established at the time of diagnosis. Multimodality therapy that includes surgery can be accomplished in selected patients with locally advanced pancreatic cancer and is associated with a median overall survival that approximates earlier stages of disease. (Surgery 2017;160:XXX-XXX.).
BACKGROUND:Patients with locally advanced pancreatic cancer have historically been considered inoperable. The purpose of this report was to determine resectability rates for patients with locally advanced pancreatic cancer based on our recently described definitions of type A and type B locally advanced pancreatic cancer. METHODS: An institutional prospective pancreas cancer database was queried for consecutive patients with locally advanced pancreatic cancer treated between January 2009 and June 2017. All pretreatment imaging was re-reviewed and patients were categorized as locally advanced pancreatic cancer type A or type B. Demographics, induction therapy, resection type, and outcomes were reviewed. RESULTS: We identified 108 consecutive patients; 12 were excluded from analysis due to the absence of available pretreatment imaging or they had not yet completed all intended neoadjuvant therapy. Of the remaining 96 patients (45 type A, 51 type B), disease progression occurred in 19 (20%) during induction therapy and 30 (31%) were deemed inoperable at final preoperative restaging. Therefore, 47 (49%) of 96 patients were taken to surgery and 40 (42%) underwent successful resection (28 [62%] of 45 type A and 12 [24%] of 51 type B); an RO resection was achieved in 32 (80%). Metastatic disease was found intraoperatively (6 at laparoscopy, 1 at laparotomy) in 7 (15%) of 47 patients. There were no mortalities; 6 (15%) patients experienced major postoperative complications. Resected patients had a median overall survival of 38.9 months. CONCLUSION: Locally advanced pancreatic cancer can be dichotomized into type A and B with distinctly different probabilities of completing all therapy to include surgery; thereby allowing goals of therapy to be established at the time of diagnosis. Multimodality therapy that includes surgery can be accomplished in selected patients with locally advanced pancreatic cancer and is associated with a median overall survival that approximates earlier stages of disease. (Surgery 2017;160:XXX-XXX.).
Authors: Alice C Wei; Fang-Shu Ou; Qian Shi; Xiomara Carrero; Eileen M O'Reilly; Jeffrey Meyerhardt; Robert A Wolff; Hedy L Kindler; Douglas B Evans; Vikram Deshpande; Joseph Misdraji; Eric Tamm; Dushyant Sahani; Malcolm Moore; Elliot Newman; Nipun Merchant; Jordan Berlin; Laura W Goff; Peter Pisters; Mitchell C Posner Journal: Ann Surg Oncol Date: 2019-08-15 Impact factor: 5.344
Authors: Georgios Gemenetzis; Alex B Blair; Minako Nagai; William R Burns; Christopher L Wolfgang; Jin He; Vincent P Groot; Ding Ding; Ammar A Javed; Richard A Burkhart; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; John L Cameron; Amol Narang; Daniel Laheru; Kelly Lafaro; Joseph M Herman; Lei Zheng Journal: Ann Surg Oncol Date: 2021-08-27 Impact factor: 5.344
Authors: Caitlin A McIntyre; Noah A Cohen; Debra A Goldman; Mithat Gonen; Eran Sadot; Eileen M O'Reilly; Anna M Varghese; Kenneth H Yu; Vinod P Balachandran; Kevin C Soares; Michael I D'Angelica; Jeffrey A Drebin; T P Kingham; Peter J Allen; Alice C Wei; William R Jarnagin Journal: J Surg Oncol Date: 2021-10-31 Impact factor: 3.454
Authors: Naveen M Kulkarni; Erik V Soloff; Parag P Tolat; Guillermo P Sangster; Jason B Fleming; Olga R Brook; Zhen Jane Wang; Elizabeth M Hecht; Marc Zins; Priya R Bhosale; Hina Arif-Tiwari; Lorenzo Mannelli; Avinash R Kambadakone; Eric P Tamm Journal: Abdom Radiol (NY) Date: 2020-03
Authors: Haidy Nasief; William Hall; Cheng Zheng; Susan Tsai; Liang Wang; Beth Erickson; X Allen Li Journal: Front Oncol Date: 2020-01-08 Impact factor: 6.244